|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
����ϩ |
|
Ƥ������ |
|
�������� |
|
���� |
| ��������������� | |
|
����� |
|
���� |
|
����� |
| PubMed | |
|
Article by |
|
Article by |
|
Article by |
����ϩ��������ϩҩ����Ƥ������������о�
�����, ����, �����
���ľ�ҽ��ѧ����ҽԺƤ���� ���� 710032
����ϩ��Ϊ��֢���ʲ�����һЩƤ�����ķ�����չ,������ϩҩ���������Ƥ����Ҳȡ����һ������Ч���ع˰���ϩ��Ƥ�����йص�����,�Բ�������ϩ�ڲ���Ƥ���������е������Լ�������ϩ������Ƥ�����е�Ӧ�á�
[2] Wedi B, Kapp A. Pathophysiological role of leukotrienes in dermatological diseases: potential therapeutic implications. BioDrugs, 2001,15:729-743.
[3] Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol, 2003, 28:123-127.
[4] Nakamura K, Imakado S, Takizawa M, et al. Exacerbation of pustulosis palmaris et plantaris after topical application of metals accompanied by elevated levels of leukotriene B4 in pustules. J Am Acad Dermatol, 2000,42:1021-1025.
[5] Penning TD, Russell MA, Chen BB, et al. Synthesis of potent leukotriene A(4) hydrolase inhibitors. Identification of 3-[methyl[3-[4-(phenylmethyl)phenoxy] propyl] amino] propanoic acid.J Med Chem, 2002, 45:3482-3490.
[6] Askonas LJ, Kachur JF, Villani-Price D, et al. Pharmacological characterization of SC-57461A (3-[methyl[3-[4-(phenylmethyl)phenoxy] propyl] amino] propanoic acid HCl), a potent and selective inhibitor of leukotriene A(4) hydrolase I: in vitro studies. J Pharmacol Exp Ther, 2002, 300:577-582.
[7] Prieto JM, Recio MC, Giner RM, et al. Influence of traditional Chinese anti-inflammatory medicinal plants on leukocyte and platelet functions. J Pharm Pharmacol, 2003, 55:1275-1282.
[8] Ito R, Miura K, Odajima Y, et al.Effect of pranlukast on histamine release and leukotriene c4 (ltc4) generation from human peripheral basophils. Arerugi, 2004,53:19-23.
[9] Yanase DJ, David-Bajar K. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. J Am Acad Dermatol, 2001, 44:89-93.
[10] Pei AY, Chan HH, Leung TF. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: a pilot study. Pediatr Allergy Immunol, 2001, 12:154-158.
[11] Concha del Rio LE, Arroyave CM. A leukotriene antagonist (montelukast) in the treatment of atopic dermatitis in pediatric patients. Rev Alerg Mex, 2003, 50:187-191.
[12] Crow DW, Marsella R, Nicklin CF. Double-blinded, placebo-controlled, cross-over pilot study on the efficacy of zileuton for canine atopic dermatitis. Vet Dermatol, 2001, 12:189-195.
[13] Senter DA, Scott DW, Miller WH Jr. Treatment of canine atopic dermatitis with zafirlukast, a leukotriene-receptor antagonist: a single-blinded, placebo-controlled study. Can Vet J, 2002, 43:203-206.
[14] Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol, 2004, 113:134-140.
[15] Eymard B, Cousin F, Nicolas JF. Prevention of aspirin-induced angioedema with an association of leukotriene inhibitors and antihistamines. Ann Dermatol Venereol, 2003, 130:787-788.
[16] Bonadonna P, Lombardi C, Senna G,et al. Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. J Am Acad Dermatol, 2003, 49:714-716.
[17] Zemtsov A, Bucchino S, McDowell MR. Potential use of leukotriene inhibitors in treatment of psoriasis. Dermatology, 2003, 206:179-180.
[18] Jamaleddine G, Diab K, Tabbarah Z, et al. Leukotriene antagonists and the Churg-Strauss syndrome. Semin Arthritis Rheum, 2002, 31:218-227.
[19] Kobayashi S, Ishizuka S, Tamura N, et al. Churg-Strauss syndrome (CSS) in a patient receiving pranlukast. Clin Rheumatol, 2003, 22:491-492.